Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

MannKind Corporation (MNKD)

4.07   -0.09 (-2.16%) 03-17 16:00
Open: 4.11 Pre. Close: 4.16
High: 4.145 Low: 3.99
Volume: 6,175,763 Market Cap: 1,074(M)

Technical analysis

as of: 2023-03-20 7:47:41 AM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 5.91     One year: 6.69
Support: Support1: 3.99    Support2: 3.31
Resistance: Resistance1: 5.06    Resistance2: 5.73
Pivot: 4.63
Moving Average: MA(5): 4.19     MA(20): 4.81
MA(100): 4.68     MA(250): 4.07
MACD: MACD(12,26): -0.3     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 5.9     %D(3): 4.9
RSI: RSI(14): 27.1
52-week: High: 5.73  Low: 2.6
Average Vol(K): 3-Month: 3,515 (K)  10-Days: 3,731 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ MNKD ] has closed above bottom band by 13.2%. Bollinger Bands are 81.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.16 - 4.18 4.18 - 4.2
Low: 3.92 - 3.95 3.95 - 3.98
Close: 4.02 - 4.07 4.07 - 4.11

Company Description

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

Headline News

Tue, 14 Mar 2023
MannKind (MNKD) Shares Cross Below 200 DMA - Nasdaq

Mon, 13 Mar 2023
MannKind Becomes Oversold (MNKD) - Nasdaq

Thu, 09 Mar 2023
After Hours Most Active for Mar 9, 2023 : SWN, GRAB, ATCO, BAC ... - Nasdaq

Tue, 07 Mar 2023
MannKind Corporation to Participate in Oppenheimer 33rd Annual ... -

Mon, 06 Mar 2023
MannKind Corp (MNKD) has fallen -10.41% in a Week, Should You Hold? - InvestorsObserver

Mon, 27 Feb 2023
SVB Leerink Comments on MannKind Co.'s Q1 2023 Earnings ... - MarketBeat

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 263 (M)
Shares Float 260 (M)
% Held by Insiders 6.1 (%)
% Held by Institutions 48.9 (%)
Shares Short 34,320 (K)
Shares Short P.Month 29,270 (K)

Stock Financials

EPS -0.26
EPS Est Next Qtl -0.19
EPS Est This Year -0.92
EPS Est Next Year -0.76
Book Value (p.s.) -0.75
Profit Margin (%) -128
Operating Margin (%) -111.7
Return on Assets (ttm) -20
Return on Equity (ttm) 0
Qtrly Rev. Growth 47.7
Gross Profit (p.s.) 0.13
Sales Per Share 0.28
EBITDA (p.s.) -0.31
Qtrly Earnings Growth 0
Operating Cash Flow -91 (M)
Levered Free Cash Flow -86 (M)

Stock Valuations

PE Ratio -15.84
PEG Ratio -0.5
Price to Book value -5.43
Price to Sales 14.05
Price to Cash Flow -11.82

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2017-03-02
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.